Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-19

Study Completion Date

2019-03-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).

NCT01242813

TNF-receptor Associated Periodic Syndromes (TRAPS)

COMPLETED PHASE2

Eye and Immunogenetic Features of Sarcoidosis

NCT00379275

Sarcoidosis Uveitis

COMPLETED

Mycophenolate for Pulmonary Sarcoidosis

NCT00262132

Pulmonary Sarcoidosis

TERMINATED PHASE3

The Diagnostic and Prognostic Role of SAA in Intrathoracic Sarcoidosis

NCT05811962

Sarcoidosis, Pulmonary

COMPLETED

Study of Eye Tissue for Sarcoidosis

NCT00001278

Sarcoidosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Sarcoidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACZ885

ACZ885 (300 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Group Type EXPERIMENTAL

ACZ885

Intervention Type DRUG

ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Placebo

Placebo (0 mg/2 mL) will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACZ885

ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Intervention Type DRUG

Placebo

Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Canakinumab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female subjects ages 18 to 80 years of age (both inclusive)
* Pulmonary sarcoidosis disease duration of ≥1 year
* Clinically active disease demonstrated either by a biopsy (any organ) or by bronchoalevolar lavage (lymphocytosis \>15%, CD4+/CD8+ ration\>3.5, CD103+/CD4+/CD4+ ratio \<0.2). Patients must also have all of the following criteria:

1. MMRC dyspnea scale ≥1
2. Threshold FVC 50 - 90% of predicted
3. Evidence of parenchymal lung involvement by HRCT at screening or by historical radiological evidence (e.g. CT, MRI or x-ray)

Exclusion Criteria

* Treated pulmonary hypertension
* Previous exposure to concomitant treatment according to the following criteria:

1. Prednisone \>15 mg/day or changes in prednisone dose in the 8 weeks prior to screening
2. More than one immune-modulator (i.e., methotrexate, azathioprine, leflunomide, hydroxychloroquine) or changes in their dosing levels within 12 weeks of randomization.
3. Mycophenolate use within 12 weeks of randomization
* Prior treatment with any biologic drug targeting the immune system within 180 days of randomization or history of any previous use of rituximab
* History of bleeding disorder
* Forced vital capacity (FVC) \<50% of predicted
* Extra-pulmonary sarcoidosis as primary treatment indication (e.g., involving brain, heart, eye and renal disease with significant hypercalcemia)
* Any conditions or significant medical problems which in the opinion of the investigator immune-compromise the patient and/or places the patient at unacceptable risk for immunomodulatory therapy, such as:

1. Absolute neutrophil count (ANC) \<LLN (1,500/μl)
2. Thrombocytopenia CTCAE v4.03 Grade 1: Platelets \<LLN (75.0 x 10exp9/L)
3. Any active or recurrent bacterial, fungal (with exception of onychomycosis) or viral infection
4. Presence of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C infections based on screening lab results
5. Presence of active or latent tuberculosis (Tb). If historical Tb result is available, Tb status needs to be confirmed pre-randomization as determined by screening laboratory measurements.
6. Clinical evidence or history of multiple sclerosis or other demyelinating diseases, or Felty's syndrome
* Live vaccinations within 3 months prior to the start of the trial
* Current severe progressive or uncontrolled disease which in the judgment of the clinical investigator renders the patient unsuitable for the trial
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of contraception defined in the protocol for the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No